Targets › GRB2
2 programs from 1 company in 2 trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Jul 2027.
Non-enzymatic adapter protein that plays a pivotal role in precisely regulated signaling cascades from cell surface receptors to cellular responses, including signaling transduction and gene expression. Thus, participates in many biological processes including regulation of innate and adaptive immunity, autophagy, DNA repair or necroptosis. (UniProt, P62993)
Open in Phaseline: the race on GRB2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bio-Path Holdings | BP1001 Liposomal Grb-2 antisense oligonucleotide (GRB2 mRNA inhibitor) | GRB2 | Phase 2 | Acute Myeloid Leukemia (AML) | Dec 2027 |
| Bio-Path Holdings | BP1001-A Liposomal Grb2 antisense oligonucleotide | GRB2 | Phase 1 | Solid Tumor, Adult | Jul 2027 |
Solid Tumor, Adult (1) Acute Myeloid Leukemia (AML) (1)
other (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.